Market: KLS |
Currency:
Address:
π M&A Historical Chart
π Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
10-25%
-
Upcoming Earnings Date:
-
π° Dividend History
No dividend history available.
π
Earnings & EPS History for M&A
No earnings history available for this symbol.
π° Related News & Research
-
$300 Million Revolving Credit Agreement: Definitions, Terms, and Lender Information for Energy & Transportation (2026)
February 20, 2026
Pinnacle West Capital Corporation: Detailed Investor Update on New Credit Agreements Pinnacle West Capital Corporation Announces Major Five-Year Credit Facility Amendments Key Points for Investors…
-
NexPoint Diversified Real Estate Trust (NXDT) Files 8-K on Material Definitive Agreement and Financial Obligation β February 2026
February 20, 2026
NexPoint Diversified Real Estate Trust 8-K Filing Analysis NexPoint Diversified Real Estate Trust (NXDT) 8-K Filing: Key Developments Investors Must Know Summary of Key Points…
-
VSee Health, Inc. Enters Managed Services and $2 Million Stock Purchase Agreements with GoMyRx β SEC 8-K Filing Details
February 20, 2026
VSEE Health, Inc. Files Form 8-K: Stock Purchase Agreement and Key Company Updates VSEE Health, Inc. (NASDAQ: VSEE), an emerging growth company, has filed a…
-
Getty Realty Corp. Underwriting Agreement and Forward Confirmation Details for 2026 Public Offering
February 20, 2026
Getty Realty Corp. Announces Public Offering of Common Stock and Forward Sale Agreements Getty Realty Corp. Announces Major Common Stock Offering and Forward Sale Agreements…
-
Spartacus Acquisition Corp. II 2026 Audited Balance Sheet, IPO Financials, and Shareholder Information
February 20, 2026
Spartacus Acquisition Corp. II: Audited Balance Sheet and IPO Details – Investor Insights Spartacus Acquisition Corp. II: Audited Balance Sheet and IPO Details – Investor…
-
Artiva Biotherapeutics, Inc. 8-K Filing: Company Information, Address, and SEC Details (2026)
February 20, 2026
NIL Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers are encouraged to conduct their own research and consult…
-
Expeditors International of Washington, Inc. Announces Employment Agreement with Roberto A. Martinez β SEC 8-K Filing Details 8
February 20, 2026
Expeditors International of Washington, Inc. Files Form 8-K: Key Company Disclosure for Investors BELLEVUE, WA, May 23, 2025 β Expeditors International of Washington, Inc. (βExpeditorsβ…
-
Hansoh Pharmaceutical’s Aumolertinib Mesylate Tablets Approved in EU as Monotherapy for Advanced EGFR-Mutated NSCLC 1
February 20, 2026
Hansoh Pharmaceutical Group – EU Approval for Aumolertinib Mesylate Tablets Hansoh Pharmaceutical Group Receives Landmark EU Approval for Aumolertinib Mesylate Tablets as Monotherapy in Advanced…
-
Tianli International Holdings Director Increases Shareholding and Announces On-Market Share Repurchase (February 2026)
February 20, 2026
Tianli International Holdings Limited: Director Share Purchase and On-Market Share Repurchase Tianli International Holdings Limited: Significant Share Transactions by Director and Company Key Highlights Director’s…
-
Pengo Holdings Signs Cooperation Framework with Guangju Zhongsheng to Develop Bajie Animation IP and Expand Digital Content Business 1 2 3
February 20, 2026
Pengo Holdings Group Limited Announces Strategic Cooperation Framework with Guangju Zhongsheng Holdings Pengo Holdings Group Limited Announces Strategic Cooperation Framework with Guangju Zhongsheng Holdings Date:…
π View more Reports